NCT04799639View on ClinicalTrials.gov

Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

June 17, 2024

Study Completion Date

June 24, 2024

Conditions
Cervical CancerChemotherapy EffectProgrammed Cell Death 1 Receptor / Antagonists & InhibitorsNeoadjuvant Therapy
Interventions
DRUG

Sindilimab +paclitaxel+ cisplantin

standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles

Trial Locations (1)

510000

Sun Yat-sen University cancer center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT04799639 - Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer | Biotech Hunter | Biotech Hunter